■ INTRODUCTION
Eukaryotic cells have evolved a diverse repertoire of enzymes for catalyzing potent chemical modifications on proteins that dictate diverse signaling events. 1, 2 For example, nearly 600 kinases exist in human cells to control phosphorylation, and dysregulation of this complex and interconnected signaling network is often linked to diseases such as cancer. 3 The endogenous mitogen-activated protein kinase (MAPK) cascade is one of the central signaling pathways that regulates numerous cellular processes. 4, 5 As two essential nodes at the end of the MAPK cascade, extracellular signal-regulated kinase (ERK) and p38 receive upstream signals and shuttle between cytoplasm and nucleus to phosphorylate more than 150 substrates participating in regulation of gene expression, cell proliferation, as well as diverse cellular responses. 6, 7 In addition, ERK can directly phosphorylate almost all the upstream components of the receptor tyrosine kinase (RTK)-RAS-MAPK cascade to mediate the negative feedback regulation. 8 Misfunction of MAPK cascade is considered as a hallmark in cancer cells including melanoma and colorectal cancers, 9, 10 and has also been connected to immune diseases. 11 Nevertheless, methods for precise tuning of the endogenous MAPK cascade are highly challenging, particularly in a spatial− temporally controlled fashion. 12 For example, although smallmolecule modulators have been developed for targeting the MAPK pathway, they often have certain off-target effects, particularly among the isoforms of MAPK family enzymes. 3, 13, 14 Meanwhile, optogenetics and chemical genetic strategies require genetic manipulation and overexpression of the kinase of interest that may perturb its native cellular functions. 15−18 Diverse effector proteins have been evolved by bacteria to modulate signaling pathways inside host cells with high specificity. 19, 20 For example, OspF is a phospho-lyase from Shigella spp. that can be secreted through a Type III secretion system (T3SS) into host cells to specifically dephosphorylate phosphothreonine at residue 202 on ERK and residue 180 on p38, respectively (Scheme 1 and Figure S1 ). 21, 22 The resulting dehydrobutyrine cannot be rephosphorylated by its upstream kinases and thus permanently abrogated ERK and p38 activity (Scheme 1B). 21 Inspired by the high specificity of OspF toward ERK and p38 as opposed to other kinases including other members of the MAPK family, we decided to employ this phospho-lyase to modulate the endogenous MAPK signaling cascade. However, since the constitutively active form of OspF will irreversibly inhibit ERK and p38 activity and thus permanently turn off the MAPK signaling cascade, temporally controlled activation of OspF is highly desired. Previous methods relying on controlled expression of OspF protein have a poor temporal resolution, 23 and are exceedingly difficult for applications in live animals. We envisioned that our recently developed genetically encoded bioorthogonal decaging strategy would enable precise and temporally controlled activation of OspF under living conditions. Herein, by bioorthogonal engineering and targeting of the bacterial effector OspF to different subcellular compartments (e.g., cytosol versus nucleus), we report spatial−temporally controlled modulation of the endogenous MAPK signaling cascade in living systems by small-molecule triggers or light.
■ RESULTS AND DISCUSSION
Engineering an Optically Controlled OspF (OspF*) for Living Cells. We started by engineering an optically controlled OspF in living cells based on the genetic code expansion system. 24 The photocaged lysine analogues such as ONBK 25, 26 and other o-nitrobenzyl caged 27−29 or coumarin lysines 30 have been previously developed for controlling lysinedependent protein activity inside living cells. As lysine 134 (K134) is the catalytic residue for OspF's phospho-lyase activity, 22 we used ONBK to replace OspF's K134 residue (Scheme 1B). The resulting protein OspF-K134ONBK (termed OspF*) completely lost its phosphothreonine lyase activity similar to the catalytically inactive OspF-K134A mutant until the 365 nm light-mediated photo-decaging (Scheme 1B). The expression of OspF* was first verified by multiple methods including immunoblotting, flow cytometry analysis, as well as mass spectrometry analysis (Figure 1A and Figures S2 and S3A,D), followed by examining its photoactivation property in live HEK293T cells. Before photolysis, we used PMA (phorbol 12-myristate 13-acetate), a protein kinase C (PKC) activator, to stimulate the endogenous ERK/ p38 phosphorylation and activate the MAPK signaling cascade. Interestingly, the phosphorylation levels of endogenous ERK/ p38 were completely eliminated in cells harboring OspF* after 365 nm light irradiation for 5 min ( Figure 1A ,B and Figure  S4 ), whereas no variation of ERK/p38 phosphorylation was observed in cells without photoactivation ( Figure 1A ,B and Figure S4 ). Furthermore, no phosphorylation change was detected on ERK/p38 when the same batch of cells without OspF* were treated with the same dosage of light, which confirmed that the low dosage of light we used did not cause the phosphorylation change on ERK, p38, as well as their substrates inside cells ( Figure S5 ). Finally, we found that expression of OspF* did not affect the phosphorylation status of JNK (another MAPK that is not OspF's substrate) as well as other kinases we tested including IκBα and Akt before and after photoactivation ( Figure 1A and Figure S6 ), which further confirmed the high specificity of OspF toward ERK/p38. We also constructed a stable HEK293T cell line that constitutively We then applied OspF* for temporal modulation of the MAPK pathway. First, we showed that, upon photoactivation of OspF* inside cells, the attenuation of ERK/p38 phosphorylation was observed as fast as 5 min ( Figure S8 ) while the protein level of OspF* was not changed even 60 min after photoactivation. We then employed a luciferase reporter, SRE-luc, to monitor OspF activity in living cells. 31 SRE-luc reporter responds to ERK/MAPK signaling, allowing the luciferase expression level correlated with the endogenous ERK activity. For example, the reactivated OspF* attenuated ERK activity constitutively and thus reduced luciferase expression and the bioluminescence signal. Indeed, an obvious decrease of bioluminescence signal was detected in PMA stimulated cells harboring OspF* after 5 min of light treatment, which was similar to the effect of OspF-WT ( Figure 1C ). In contrast, no bioluminescence variation was observed in the same batch of cells without light treatment ( Figure 1C ). We further examined the effect of OspF* on gene transcription. Previous studies demonstrated that inactivation of ERK/p38 would block the immune response mediated by the MAPK pathway such as the transcription and secretion of cytokine including interleukin-2 (IL-2) and interleukin-8 (IL-8). 23, 32 Indeed, upon photoactivation of OspF* in cells prestimulated by PMA, a dramatic reduction on transcription and secretion of IL-8 was observed ( Figure 1D and Figure S9 ). Taken together, our engineered photoactivatable OspF can modulate the endogenous MAPK signaling in living cells with high temporal resolution.
Spatial−Temporal Modulation of OspF* by Light. ERK is known to shuttle between the nucleus and cytoplasm and phosphorylate a series of substrates with different physiological outputs. 6 Activated ERK can translocate into the nucleus to phosphorylate transcription factors such as Myc proto-oncogene protein (c-MYC) to induce gene expression and cell proliferation. Meanwhile, phosphorylated ERK remains in the cytoplasm to phosphorylate over 50 substrates and mediate biological processes such as negative feedback regulation. Modulating ERK's activity with spatial resolution may help to dissect its functions in different subcellular regions. Small-molecule ERK inhibitors will block all of 's activity that lacksspatial resolution. In contrast, subcellulartargeted OspF* may allow modulation of ERK's activity in the nucleus as opposed to cytoplasm with high spatial resolution. We first generated nucleus-located OspF* (nu-OspF*) by fusing a bipartite nuclear localization sequence (NLS) from nucleoplasmin to the N-terminal of OspF*, while two K to A mutations were introduced to this NLS to render the resulting OspF* exclusively cytosol-located (cyt-OspF*) ( Figure  2A) . 33, 34 Subcellular fractionation and immunoblotting analysis confirmed the proper subcellular localization as well as the similar expression levels of nu-OspF* and cyt-OspF* in the nucleus and cytoplasm of HEK293T cells ( Figure S10 ). Flow cytometric analysis verified the expression of both nu-OspF* and cyt-OspF* in most cells ( Figure 2B and Figure  S3B ,C,E,F), while immunofluorescence analysis also verified the adequate expression as well as the proper subcellular localization of nu-OspF* and cyt-OspF* in the majority of cells ( Figure 2C and Figure S11 ). Next, a significantly decreased ERK phosphorylation was observed in cells after photoactivation of either nu-OspF* or cyt-OspF* ( Figure  S12 ). Furthermore, we analyzed the extent of ERK phosphorylation in the nucleus and cytoplasm after activation of subcellular-targeted OspF*. Immunoblotting results showed that phosphorylation of ERK in the nucleus was significantly decreased after nu-OspF* activation, but negligible variation was detected on cytosolic ERK. In contrast, a significant decrease of ERK phosphorylation in the cytoplasm was detected after optical rescue of cyt-OspF* inside cells ( Figure  S10 ). These results proved that our subcellular-targeted OspF* could modulate the extent of ERK phosphorylation in different cellular compartments.
To demonstrate the spatial modulation capability of our subcellular-located OspF*, we monitored the phosphorylation states of ERK's nuclear substrate c-MYC as well as the cytoplasmic substrate p90 ribosomal S6 kinase (p90RSK), respectively. As an oncogenic transcriptional factor, the amplification of c-MYC has been shown as a hallmark in cancer and malignant tumor generation. 35 Phosphorylation of c-MYC on residue 62 mediated by ERK promotes its stability and transcriptional activity. 36 The cytoplasmic substrate p90RSK plays an important role in transcription and cell growth regulation. 37 Once p90RSK is phosphorylated on residues T359/S363 by ERK in cytoplasm, it would phosphorylate many targets in both the cytoplasm and nucleus. Photoactivation on cells harboring nu-OspF* led to a significant decrease of c-MYC phosphorylation within 5 min and degradation of c-MYC in 60 min, while no obvious variation on p90RSK was observed ( Figure 2D ,E and Figure  S13 ). In contrast, upon photoactivation on cells expressing cytOspF*, the phosphorylation of p90RSK was inhibited within 5 min ( Figure 2F,G) . In addition, less decrement of c-MYC phosphorylation (5 min) and protein abundance (60 min) was detected at the same time point in comparison with cells harboring nu-OspF* ( Figure 2D ,E and Figures S13 and S14A) . Moreover, we used the MEK1/2 inhibitor U0126 to inhibit ERK phosphorylation in cytosol and investigated the variation of c-MYC phosphorylation and abundance. No alternation of c-MYC phosphorylation and protein abundance was observed within 30 min, and a decreased phosphorylation was detected at 45 min ( Figure S14B ). This is similar to the results acquired from cells harboring cyt-OspF* that inactivated ERK in cytosol. Therefore, specific targeting of nucleus-located ERK can downregulate c-MYC activity and stability without interfering with its cytosolic substrate p90RSK.
Similarly, activation of cytosol-located OspF* did not affect nuclear ERK and c-MYC activity in a short time (within ∼30 min) ( Figure 2G and Figure S14A ). After a longer incubation time (60 min or above), no more cytosol-activated ERK can be translocated into the nucleus because of the inhibition of ERK phosphorylation in cytosol, which caused the decrease of c-MYC's phosphorylation level as well as protein abundance ( Figure 2G and Figures S13 and S14A ). In addition, we also verified our subcellular specific photoactivation strategy in HEK293T cells stably expressing the MmPylRSNBK-1/ tRNAPyl CUA pair. Either nu-OspF* or cyt-OspF* was expressed in this stable HEK293T cell line, and the expression of full-length OspF* was analyzed by flow cytometry and immunoblotting ( Figures S3H,I ,K,L and S15). Similar to the cells transiently transfected with nu-OspF* and cyt-OspF*, ERK phosphorylation was attenuated 5 min after light irradiation in both cells. Alternation on p90RSK phosphorylation was only observed in cells harboring cyt-OspF*, and a decrease of c-MYC phosphorylation and protein abundance was detected only in the nu-OspF* expressed cells within 5 min after optical rescue ( Figure S15 ). Taken together, our engineered OspF can modulate endogenous ERK functions with high spatial−temporal resolution.
Engineering a Chemically Controlled OspF (OspF c ) for Living Animals. We have shown that our engineered OspF* could be applied for modulation of endogenous MAPK signaling cascade in living cells, which provided high spatial− temporal resolution desired for mechanistic study in vivo. Meanwhile, small-molecule-mediated chemical-rescue strategies possess higher penetration capability in deep tissue and are thus more compatible for kinase signaling modulation at the tissue and animal level. Since we have recently developed the small-molecule-mediated chemical-decaging strategy to rescue lysine-dependent protein activity in living animals, 38−41 we created a chemically rescued OspF (termed OspF c ) for applications in living animals. The inverse electron demand Diels−Alder reaction (iDA) between TCOK-a and Me 2 -Tz (3,6-dimethyl-1,2,4,5-tetrazine) has been shown as a rapid and efficient bioorthogonal cleavage reaction for intracellular protein activation in both prokaryotic and eukaryotic systems;
38,39,42 we site-specifically incorporated the chemically caged lysine-TCOK-a into OspF at residue K134, and the resulting OspF c (OspF-K134TCOK) exhibited no phospholyase activity (Scheme 1B and Figure S1 ). The addition of the decaging reagent Me 2 -Tz would regenerate free lysine at K134 with its phospho-lyase activity rescued (Scheme 1B and Figure  S1 ). Indeed, our immunoblotting results showed that the lyase activity of OspF c against ERK and p38 can be effectively rescued after treatment with 100 μM Me 2 -Tz ( Figure 3A) . We also performed a time course study to show the stability of OspF c and its effect on endogenous MAPK signaling after chemical decaging. Immunoblotting results showed that an obviously attenuated phosphorylation level of ERK and p38 was observed within 10 min after Me 2 -Tz treatment and can sustain for over 60 min ( Figure S16 ). Meanwhile, no apparent change of OspF c abundance was detected even 60 min after chemical decaging ( Figure S16 ). We then employed the aforementioned luciferase reporter, SRE-luc, to monitor OspF c activity in living cells. Indeed, an obvious decrease of bioluminescence signal was detected in PMA stimulated cells harboring OspF c after 100 μM Me 2 -Tz treatment, which was similar to the effect of OspF-WT ( Figure 3B ). In contrast, no bioluminescence variation was observed in the same batch of cells without Me 2 -Tz treatment ( Figure 3B Stimulated HEK293T cells expressing OspF c and SRE-luc reporter were injected into living mice subcutaneously, followed by tail vein injection of Me 2 -Tz (50 μL, 300 mM, equal to 66 mg/kg body weight). As a control, a noncleavable lysine analogue, CbzK (benzyloxycarbonyl caged lysine), was incorporated into OspF at the same residue K134 to generate an inactivated counterpart (OspF-K134CbzK). Cells harboring OspF-K134CbzK and SRE-luc were subcutaneously injected into the other leg on the same mouse ( Figure 3C ). Bioluminescence imaging showed that the lyase activity of OspF c can be effectively rescued with Me 2 -Tz treatment, as made evident by the significantly attenuated bioluminescence signal in mice upon Me 2 -Tz addition ( Figure 3D and Figure  S17 ). In contrast. a similar bioluminescence level remained in the leg injected with OspF-K134CbzK-expressing cells with and without Me 2 -Tz treatment. Therefore, our chemicaldecaging strategy on OspF can be applied to living animals.
Precise Tuning of T Cell Responses by Chemically Controlled, Subcellular-Targeted OspF c . We further expanded our chemically rescued OspF c to tune immune responses. T cell receptor (TCR) stimulation can lead to T cell activation with a series of immune responses such as cytokine production and release ( Figure 4A) . 43−45 As a key component in TCR signaling, activated ERK will translocate into the nucleus and regulate the expression of cytokines such as IL-2 and IL-8. 46 Meanwhile, ERK also phosphorylates and inhibits the activity of a panel of upstream components in cytosol including MEK1, BRAF, SOS, and Lck to avoid overstimulation and hyperactivation of TCR signaling ( Figure  4B) . 47, 48 For immunotherapeutic strategies such as adoptive T cell therapy, overstimulation of the MAPK cascade on native or engineered T cells may lead to cytokine release syndrome (also called cytokine storm), a life-threatening immune response.
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To this end, specific silencing of ERK-induced cytokine expression in the nucleus without affecting the cytosolic signaling loops may become a viable strategy for suppressing cytokine release without affecting T cell activity. We envision that our subcellular-targeted OspF c can be used to specifically inhibit ERK's activity in the nucleus with the cytosolic feedback regulation unaffected ( Figure 4B ).
We first surveyed the cytotoxicity of our chemical-decaging method on T cells. Jurkat cells treated with different concentrations of TCOK-a (0.5−2 mM) or Me 2 -Tz (100− 500 μM) were subject to the MTS assay, and no apparent cell death was observed ( Figure S18 ). These results proved that our chemical-rescue strategy is compatible with immune cells. Next, we modulated the endogenous ERK activity by our nucleus-located OspF c (nu-OspF c ) in T cells. To acquire a better expression efficiency, we introduced the plasmid encoding nu-OspF c into Jurkat cells by electroporation, which were then subject to PMA and ionomycin stimulation before chemical rescue of OspF c . The immunoblotting results showed that the lyase activity of nu-OspF c against ERK can be effectively rescued after the treatment with 100 μM Me 2 -Tz ( Figure 4C ). We also investigated the impact of nu-OspF cmediated subcellular ERK inhibition on cytosolic signaling loops, which showed that rescue of nu-OspF c in stimulated Jurkat cells did not change the feedback regulation on BRAF phosphorylation ( Figure 4C ). We further monitored the phosphorylation state of lymphocyte-specific protein tyrosine kinase (Lck). Activation of T cells can induce an ERKmediated feedback regulation and phosphorylation on Lck, which would interfere with the recruitment of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and sustain TCR signaling. 48 It has been previously reported that this ERK-dependent phosphorylation on Lck resulted in its conversion from p56 Lck (p56) to p59 Lck (p59). 49 Indeed, whereas the treatment of a MEK1/2 inhibitor-U0126 attenuated the formation of p59 Lck ( Figure S19) , 50 no band-shift was observed on Lck in the cells bearing nu-OspF c before and after chemical decaging ( Figure 4C ). Taken together, we showed that our nucleus-located, chemically controlled OspF c allowed precise modulation of nuclear ERK's activity without affecting its cytosolic feedback regulations.
Finally, we monitored the controlled cytokine secretion by our engineered, subcellular-located OspF c in T cells. We first confirmed that our chemical-decaging reagents TCOK-a and Me 2 -Tz did not interfere with cytokine secretion in Jurkat cells ( Figure S20 ). The nu-OspF c -expressing Jurkat cells were then stimulated by PMA and ionomycin for 10 min, followed by the addition of 100 μM Me 2 -Tz to rescue nu-OspF c activity. The secretions of IL-2 and IL-8 were found completely inhibited by chemically rescued nu-OspF c even 6 h after PMA and ionomycin stimulation ( Figure 4D , red line), whereas a continuous IL-2 and IL-8 secretion was detected in cells without nu-OspF c activation ( Figure 4D , blue line). Furthermore, the same batch of Jurkat cells was stimulated by PMA and ionomycin for 3 h before the addition of 100 μM Me 2 -Tz, which also led to a decrease of IL-2 and IL-8 secretion levels ( Figure 4D , purple line). Taken together, we showed that our OspF c -enabled spatial−temporal modulation of ERKsignaling would allow the in situ suppression of cytokine secretion without affecting other functions of T cells.
■ CONCLUSION AND OUTLOOK
Bacterial effector proteins have been previously applied for modulation of cellular signaling pathways but often lack desired spatial−temporal resolution in living systems. 23 In this work, we engineered optically and chemically controlled phospho-lyase OspF (OspF* and OspF c ) by masking its key lysine residue K134 with photocaged and chemically caged lysine analogue. Subcellular targeting of these bioorthogonalengineered OspF variants allowed us to specifically modulate the endogenous ERK and p38 activity and thus the native MAPK signaling cascade with high spatial−temporal resolution. While the nucleus-and cytosol-located OspF* allowed modulation and dissection of endogenous ERK activity in space and time, the chemically caged OspF c enabled modulation of endogenous ERK activity in living mice, making our strategy compatible with various living systems. Given the versatility of bacterial effectors that have been evolved to manipulate diverse host signaling pathways, our bioorthogonal engineering strategy on OspF may be extended to its homologues (e.g., SpvC) and other effectors to modulate or rewire cell signaling with high specificity and spatial−temporal resolution.
Dysregulation of the MAPK signaling cascade occurs frequently in melanoma, colorectal, and breast cancers. Offtarget activation or overstimulation on MAPK cascade also induces the overproduction of proinflammatory cytokines which contributes to autoimmune diseases. Inhibitors against components in this signaling pathway, particularly RAF and MEK, have been developed or are undergoing clinical trials. 12 As key nodes of the MAPK signaling cascade, ERK and p38 receive all upstream signals and regulate a number of substrates involved in different cellular processes including gene expression, cell proliferation, and immune response. Selective and spatially specific inhibition of ERK and p38 provides an attractive choice for targeting the MAPK cascade that may have lower adverse effects or can overcome adaptive drug resistance. 51, 52 Given the central role of ERK and p38 at the terminal of the MAPK cascade, our engineered OspF variants offer a powerful toolset for perturbing endogenous MAPK activity with high selectivity, subcellular specificity, as well as minute-scale temporal resolution. Finally, by introducing our nucleus-located OspF c variant into T cells, we selectively disabled ERK's nuclear function on stimulating interleukin The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acscentsci.8b00751.
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